NECLIFE · Nectar Lifesciences Ltd · Biotechnology & Drugs
NECLIFE · Nectar Lifesciences Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
54.8% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹0.44 Cr
Revenue YoY
PAT YoY
+75.6%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
0.4
P/S (TTM)
30
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| NECLIFE (this stock) | 1.1 | 0.4 | -7231.9% | -92.4% | 0 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedNectar Lifesciences Limited's FY2025-26 annual report outlines the company's strategic shift towards real estate following the divestment of its pharmaceutical businesses and non-core assets. The report highlights the company's focus on building a diversified portfolio by exploring investment opportunities in emerging growth sectors, particularly real estate. The company emphasizes a disciplined and capital-efficient growth strategy with a focus on prudent project selection, sound corporate governance, effective risk management, sustainable development, and long-term value creation. The report also mentions the re-appointment of Dr. Kuldip Kumar Bhasin as an independent director for a second term despite him attaining the age of 75, citing his extensive experience and contributions to the company's strategic objectives.
- Strategic divestment of pharmaceutical businesses and non-core assets to focus on real estate and emerging growth sectors.
- Emphasis on a disciplined and capital-efficient growth strategy with prudent project selection and sustainable development.
- Re-appointment of Dr. Kuldip Kumar Bhasin as an independent director despite reaching the age of 75, highlighting his strategic guidance and experience.
Key takeaway: Management indicates that Nectar Lifesciences Limited is transitioning its focus from pharmaceuticals to real estate and emerging sectors, emphasizing strategic diversification and sustainable growth, despite facing financial challenges indicated by a significant loss in the current fiscal year.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
2 occurrencesRecent (last 12 months)
The company was fined INR 1,80,000 plus GST by NSE and BSE for late submission of financial results and lack of advance notice, and the fines were deposited but waiver applications were denied.
Earlier (1-3 years ago)
The company received a summons from SEBI in September 2024 related to a Show Cause Notice from the GST department dated July 2022. The company has provided all required documents to SEBI and no further communication has been received since September 13, 2024.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has contingent liabilities and commitments as of 31.03.2025 and 31.03.2024, though specific amounts or details are not provided in the excerpt.
Earlier (1-3 years ago)
The company has contingent liabilities related to income tax, excise & GST, service tax, and VAT & CST matters, with potential financial impacts if adverse judgments are confirmed.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has statutory dues disputes pending before various authorities, including Income Tax Appellate Tribunals and CESTAT, related to assessment years 15-21 and financial years 05-09, with amounts not specified in the provided excerpt.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
5.29% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).